Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

Mar. 10, 2025 — A new study suggests that chronic stress and an unhealthy diet may work together to fuel the early development of pancreatic cancer, shedding light on how lifestyle factors ...

Exelixis (NASDAQ:EXEL) said on Wednesday that the U.S. FDA has approved cabozantinib for patients 12 years of age and older ...

Exelixis (EXEL) wins FDA approval for Cabometyx for advanced pancreatic and extra pancreatic neuroendocrine tumors in ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

Dublin, March 14, 2025 (GLOBE NEWSWIRE) -- The "Carcinoid Tumor Market" report has been added to ResearchAndMarkets.com's offering. The global demand for advanced carcinoid tumor treatments is ...

The significance of the findings is valuable, with implications for immunotherapy design in pancreatic ductal adenocarcinoma. The evidence was considered incomplete and partially supportive of the ...

“The COMPETE results represent a major step forward in the development of new treatment options for people living with progressive, inoperable GEP-NETs,” Dr Jonathan Strosberg, past president, North ...

Objective Despite recent advances in surgical and interventional techniques, knowledge on the management of carcinoid heart disease (CHD) remains limited. In a cohort of patients with liver metastases ...

Centre for 3D models of Health and Disease, Division of Surgery and Interventional Science, University College London, London W1W 7TY, U.K. Centre for 3D models of Health and Disease, Division of ...